| Jump to: | Authorized Access | | | Attribution | | | Authorized Requests |
- Study Description
-
Important Links and Information
-
Request access via Authorized Access
- Instructions for requestors
- Data Use Certification (DUC) Agreement
- Talking Glossary of Genetic Terms
Psoriasis is a chronic immune disease of the skin and joints that affects about 2% of the population. The most common form of psoriasis is plaque psoriasis, also called psoriasis vulgaris. A variety of drugs, including biologics, are available for treatment of moderate to severe psoriasis. When biologic agents are stopped, psoriasis can return (relapse) and often requires the biologic to be restarted and continued. No treatment program has been identified to prevent relapse of psoriasis. The study design has a lead-in period of weight-based ustekinumab treatment, with all participants receiving either 45 mg ustekinumab (<= 100 kg) or 90 mg ustekinumab (> 100 kg) administered subcutaneously at weeks 0 and 4. At week 12, participants will be assessed for a Psoriasis Area and Severity Index (PASI) 75 response to ustekinumab. Participants who do not achieve a PASI 75 score will be discontinued from the investigation and permitted to seek standard therapy.
- Study Design:
- Clinical Trial
- Study Type:
- Clinical Trial
- Total number of consented subjects: 90
- Subject Sample Telemetry Report (SSTR)
-
Request access via Authorized Access
- Authorized Access
- Publicly Available Data
- Link to other NCBI resources related to this study
- Selected Publications
- Diseases/Traits Related to Study (MeSH terms)
-
- Primary Phenotype: Psoriasis
- Authorized Data Access Requests
- Study Attribution
-
-
Co-Investigators
- Qian Xiao. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
- Joseph Mears. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
- Aparna Nathan. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
- Kazuyoshi Ishigaki. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
- Yuriy Baglaenko. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
- Noha Lim. Immune Tolerance Network, University of California San Francisco, San Francisco, CA, USA.
- Laura A. Cooney. Immune Tolerance Network, University of California San Francisco, San Francisco, CA, USA.
- Kristina M. Harris. Immune Tolerance Network, University of California San Francisco, San Francisco, CA, USA.
- Mark Anderson. Immune Tolerance Network, University of California San Francisco, San Francisco, CA, USA.
- David A. Fox. Division of Rheumatology, Department of Internal Medicine and Clinical Autoimmunity Center of Excellence, University of Michigan.
- Dawn E. Smilek. Immune Tolerance Network, University of California San Francisco, San Francisco, CA, USA.
- James G. Kruesger. Laboratory for Investigative Dermatology, The Rockefeller University, New York, NY, USA.
-
Principal Investigator
- Soumya Raychaudhuri. Center for Data Sciences, Brigham and Women's Hospital, Boston, MA, USA.
-
Co-Investigators